Atb Cap Markets Decreases Earnings Estimates for Curaleaf

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) – Research analysts at Atb Cap Markets dropped their FY2024 EPS estimates for Curaleaf in a research note issued to investors on Thursday, November 7th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings of ($0.24) per share for the year, down from their prior forecast of ($0.21). The consensus estimate for Curaleaf’s current full-year earnings is ($0.25) per share. Atb Cap Markets also issued estimates for Curaleaf’s Q4 2024 earnings at ($0.04) EPS and FY2025 earnings at ($0.14) EPS.

Other research analysts have also recently issued reports about the stock. Cormark cut shares of Curaleaf from a “moderate buy” rating to a “hold” rating in a report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.25 price target on shares of Curaleaf in a research note on Thursday, August 8th.

Curaleaf Stock Performance

CURLF stock opened at $2.04 on Monday. Curaleaf has a fifty-two week low of $1.64 and a fifty-two week high of $6.40. The company has a market capitalization of $1.33 billion, a P/E ratio of -7.03 and a beta of 0.86. The company has a 50-day simple moving average of $2.93 and a 200 day simple moving average of $3.75. The company has a quick ratio of 0.50, a current ratio of 1.09 and a debt-to-equity ratio of 0.83.

About Curaleaf

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.